uniQure N.V. Income (Loss) from Continuing Operations before Income Taxes, Domestic
uniQure N.V. (QURE) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$174.51 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-03-02
- uniQure N.V. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$174.51M.
- uniQure N.V. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$215.25M.
- uniQure N.V. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$282.53M.
- uniQure N.V. income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$96.87M, a 127.80% decline from fiscal 2021.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2025-12-31 | -$174.51M 10-K · filed 2026-03-02 |
| 2024-12-31 | -$215.25M 10-K · filed 2026-03-02 |
| 2023-12-31 | -$282.53M 10-K · filed 2026-03-02 |
| 2022-12-31 | -$96.87M 10-K · filed 2025-02-27 |
| 2021-12-31 | $348.40M 10-K · filed 2024-02-28 |
| 2020-12-31 | -$130.49M 10-K · filed 2023-02-27 |
| 2019-12-31 | -$111.82M 10-K · filed 2022-02-25 |
| 2018-12-31 | -$85.72M 10-K · filed 2021-03-01 |
| 2017-12-31 | -$60.97M 10-K · filed 2020-03-02 |
| 2016-12-31 | -$51.11M 10-K · filed 2019-02-28 |
| 2015-12-31 | -$63.30M 10-K · filed 2018-03-14 |
| 2014-12-31 | -$41.06M 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |